title: Investigation towards bivalent chemically defined glycoconjugate immunogens prepared from acid-detoxified lipopolysaccharide of Vibrio cholerae O1, serotype Inaba.
abstract: A free amino group present on the acid-detoxified lipopolysaccharide (pmLPS) of V. cholerae O1 serotype Inaba was investigated for site-specific conjugation. Chemoselective pmLPS biotinylation afforded the corresponding mono-functionalized derivative, which retained antigenicity. Thus, pmLPS was bound to carrier proteins using thioether conjugation chemistry. Induction of an anti-LPS antibody (Ab) response in BALB/c mice was observed for all conjugates. Interestingly, the sera had vibriocidal activity against both Ogawa and Inaba strains opening the way to a possible bivalent vaccine. However, the level of this Ab response was strongly affected by both the nature of the linker and of the carrier. Furthermore, no switch from IgM to IgG, i.e. from a T cell-independent to a T cell-dependent immune response was detected, a result tentatively explained by the possible presence of free polysaccharide in the formulation. Taken together, these results encourage further investigation towards the development of potent pmLPS-based neoglycoconjugate immunogens, fully aware of the challenge faced in the development of a cholera vaccine that will provide efficient serogroup coverage.
authors.affiliation: Unité de Chimie Organique, URA CNRS 2128, Institut Pasteur, 25-28, Rue du Docteur Roux, 75724 Paris Cedex 15, France. cyrille.grandjean@u-picardie.fr
authors.forename: Cyrille
authors.initials: C
authors.lastname: Grandjean
authors.forename: Alain
authors.initials: A
authors.lastname: Boutonnier
authors.forename: Bruno
authors.initials: B
authors.lastname: Dassy
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Fournier
authors.forename: Laurence A
authors.initials: LA
authors.lastname: Mulard
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology*; D022121:Cholera Vaccines / Q000737:chemistry / Q000276:immunology* / Q000494:pharmacology; D005260:Female; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology; D008070:Lipopolysaccharides / Q000737:chemistry / Q000276:immunology* / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C; D013045:Species Specificity; D013601:T-Lymphocytes / Q000276:immunology; D014614:Vaccines, Synthetic / Q000737:chemistry / Q000276:immunology* / Q000494:pharmacology; D041241:Vibrio cholerae O1 / Q000737:chemistry / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D022121:Cholera Vaccines; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D008070:Lipopolysaccharides; D014614:Vaccines, Synthetic